

# Clarivate szerepe az innovációs ciklusban




Tóth Szász Enikő

2022. január 24.

# **Emberi találékonyság és innováció az összetett kihívások megoldására**

A megbízható tartalomhoz való hozzáféréssel, fejlett adattudományi képességeinkkel és az innováció teljes életciklusára kiterjedő mély szakértelemmel segítjük az ügyfeleinket az innováció előmozdításában és védelmében.



<https://clarivate.com/>

# Az innováció életciklusa



## Kereskedelmi forgalom

Gyorsabb piacra vitel,  
mérka erősítése

## Felfedezés

Lehetőségek megállapítása

## Védelem

Megfelelő kockázatok  
felvállalása

# Clarivate teljes portfóliója



## Science Division



### Our mission

We are a trusted, indispensable partner to innovators everywhere delivering critical data, information, workflow solutions and deep domain expertise.



### Our purpose

We believe human ingenuity can transform the world and improve our future.



### Our vision

We will improve the way the world creates, protects and advances innovation.

## IP Division



## Complementary Assets Create Industry's Most Robust, End-to-End Platform Serving the Complete Research Ecosystem



### Research Cycle

#### Content Aggregation Databases



Discovery

Citation Management

#### Research Management


CRIS

Institutional Repositories

Funding Opportunities

Life Sciences

### Combined assets



Rialto Leganto

Primo Alma Summon



Vega

Dialog STEM Database

Esploro



Web of Science™

Research Assistant

Consultancy

ScholarOne

InCites

Converis

Journal Citation Reports

Healthcare Data Solutions

Derwent™

CompuMark™

CPA GLOBAL  
Turner Catledge

5+ million  
dissertations



285+ million  
journal  
articles




824+ million  
issues of  
newspapers



1.8+  
million  
e-books



7+ billion  
digital  
pages



1.9+ billion  
Citations



2+ million  
molecular  
interactions



32+ billion  
patient claims  
& EHR records



100+ million  
patent  
documents

# Clarivate & ProQuest – not only products



**~8,500**

Colleagues

Our Connected Workplace strategy enables us to build inspired and highly collaborative teams across multiple global locations

- Proud heritage
- Customer-first focus
- Commitment to excellence and innovation
- Dedication to colleague engagement



**~2,700**

Colleagues

43 Global Offices and Knowledge in 158 Countries

# Agenda

1. Clarivate's End-to-End full suite for innovation support
2. Innovation life cycle on selected example (Kyprolis)
3. Research and Discovery phase
4. Market Assessment phase
5. Clinical Testing Phase
6. Appendix

# Our premier suite of intelligence solutions

Data-driven insights spanning the entire innovation & product lifecycle

## End-to-End Solutions Suite

Research, Discovery &  
Preclinical



Market  
Assessment



Clinical



Regulatory  
Affairs



Digital  
Health



Market Defense, Access  
& Reimbursement



In-Market



<<< Products >>>

Cortellis Cloud

Web of  
Science

MetaCore,  
Target  
Druggability

Drug  
Discovery  
Intelligence

CI & Deals,  
Timeline &  
Success Rates

Clinical Trials  
& Sites  
Intelligence

Regulatory,  
CMC  
Intelligence

Digital Health  
Intelligence

Generics  
Intelligence

Fingertip  
Formulary,  
Context  
Matters

Digital  
Insights,  
Healthbase

<<< Consulting Service >>>


<<< Data & Analytics >>>

Combining expertise, data and technologies into solutions that drive optimal outcomes

# Reduce Researcher Overload

Improve the researcher experience with the best data and tools

- 1.7B cited scholarly references
- 2.6M molecular interactions
- 34K academic journals
- 450K clinical trials
- 32B unique patient claims and HER record
- 3M pharmacology records
- 1.9K US hospitals' medical device purchase volume data
- 200 global disease and market forecasts
- 245K regulatory reference documents
- 100% of US population in enrollment data by coverage type
- 3K patient segments covered in epidemiology studies
- 80K pipeline programs
- 80 medical device market overviews
- 270K variant disease associations
- 19K US and EU hospitals' diagnosis and procedure data
- 620K searchable chemistry compounds



High quality research produces greater funding opportunities for your institution

# Web of Science solutions

We support you at  
every stage of your  
research journey

- Research discovery and workflow Solutions
- Research analytics, evaluation & management Solutions
- Research publishing solutions

## Web of Science

Discover the latest research and how it fits into the world's network of ideas, people, funders and institutions with a publisher-neutral citation index trusted by leading research institutions around the world for decades.

### Publons


Get your research and scholarly contributions noticed by publishers, peers, and the world at large, or learn to peer review.

### Essential Science Indicators

Identify emerging science trends as well as influential individuals, institutions, papers, journals, and countries across 22 categories of research.

### InCites Benchmarking & Analytics

Benchmark your institution's research output against peers worldwide, identify collaborators and assess your departments and faculty with field weighted citation metrics.



[More information →](#)

### EndNote

Save time authoring papers, even when you're collaborating with a large team.

### EndNote Click

Quickly access millions of high-quality research papers with a single mouse click.

### Journal Citation Reports

Make confident decisions about where to submit your manuscript with the world's most influential and trusted resource for evaluating peer-reviewed journals.

# Cortellis solutions

Unique suite of health and life sciences analytics solutions

- A source of comprehensive, validated, selected, regularly updated data and analysis on literature, biological pathways, protocols, facilities, patient populations and global regulatory requirements

- Cortellis delivers insights from hidden data, accelerates innovation, supports clinical trial planning and increases the odds of clinical success



The screenshot displays the Cortellis Drug Discovery Intelligence platform. At the top, there's a search bar with dropdowns for 'All' and 'Search Cortellis', and buttons for 'Index Q' and 'Full Text Q'. Below the search bar are links for 'Advanced search', 'Structure search', and 'Search history'. The main interface is titled 'Cortellis Drug Discovery Intelligence' and features several analytical modules:

- Competitive Intelligence:** Shows a timeline from 07/09/2021 to 14/09/2021, filtering by 'Status: Launched'. It includes a chart of 'Active drugs coverage by highest status' (Discovery, Preclinical, Clinical) and a link to 'Competitive landscape viewer'.
- Deals Intelligence:** Displays deals from 05/09/2021 to 12/09/2021, with a specific entry for 'University of Erlangen to study efficacy of...'.
- Clinical Trials Intelligence:** Features a world map of clinical trial sites and a section for 'Clinical trials' showing a diverse group of people.
- Analysis:** Includes sections for 'Competitive landscape viewer', 'Drug Attrition Rates', 'Competitive intelligence matrix', 'Virtual merger', 'Intellectual property landscape', 'Deal Trends', 'Deal Predictions', and 'Clinical trials timeline'.

# Innovation life cycle on selected example Kyprolis

# Following Kyprolis as an example of an asset's journey

From discovery through in-market for its first indication, Multiple Myeloma



# **PHASE 1 RESEARCH, DISCOVERY AND PRECLINICAL**

# Web of Science

The most trusted literature  
and citation database

- Detect breakthrough science & emerging trends
- Identify novel technologies
- Serve an unmet need
- Pinpoint the top researchers & institutions
- Examine the research funders and collaborators
- Tap into international & emerging markets

Advance your discovery efforts by uncovering emerging scientific trends earlier and faster.

**EPOXOMICIN, A NEW ANTITUMOR AGENT OF MICROBIAL ORIGIN**

By: HANADA, M (HANADA, M); SUGAWARA, K (SUGAWARA, K); KANETA, K (KANETA, K); TODA, S (TODA, S); NISHIYAMA, Y (NISHIYAMA, Y); TOMITA, K (TOMITA, K); YAMAMOTO, H (YAMAMOTO, H); KONISHI, M (KONISHI, M); OKI, T (OKI, T)

JOURNAL OF ANTIBIOTICS  
Volume: 45 Issue: 11 Pages: 1746-1752  
DOI: 10.7164/antibiotics.45.1746  
Published: NOV 1992  
Document Type: Article  
Abstract  
An actinomycete strain No. Q996-17 produced a novel compound, **epoxomicin**, which exhibited *in vivo* **antitumor** activity against B16 melanoma. Structural studies indicated that it is a new member of the epoxy-beta-aminoketone group, and is closely related to epomycin.

Keywords  
Keywords Plus: BIOLOGICAL-ACTIVITY; MELANOMA

Author Information  
Corresponding Address: HANADA, M (corresponding author)  
▼ BRISTOL MYERS SQUIBB, RES INST, 2-9-3 SHIMOMEGURO, MEGURO KU, TOKYO 153, JAPAN

Categories/Classification  
Research Areas: Biotechnology & Applied Microbiology; Immunology; Microbiology; Pharmacology & Pharmacy

**Journal information**

Journal Of Antibiotics  
ISSN: 0021-8820  
Current Publisher: NATURE PUBLISHING GROUP, MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND  
Impact factor: Journal Citation Report  
Research Areas: Biotechnology & Applied Microbiology; Immunology; Microbiology; Pharmacology & Pharmacy  
Web of Science Categories: Biotechnology & Applied Microbiology; Immunology; Microbiology; Pharmacology & Pharmacy

**2.668**  
Journal impact factor (2019)

**Citation Network**  
In Web of Science Core  
**160**  
Citations  
All Citations  
163 In All Databases + See more citations  
Cited References  
**4**  
View Related Records  
Most Recently Cited by  
Hubbell, GE; Tepe, JJ;  
Natural product scaffold

**1** Irreversible inhibitors of serine, cysteine, and threonine proteases  
Powers, JC; Aspin, JL; ...; James, KE  
Dec 2002 | [Chemical Reviews](#)

**2** **Epoxomicin, a potent and selective proteasome inhibitor, exhibits *in vivo* antiinflammatory activity**  
Meng, LH; Mohan, R; ...; Crews, CM  
Aug 31 1999 | [Proceedings Of The National Academy Of Sciences Of The United States Of America](#)  
The proteasome regulates cellular processes as diverse as cell cycle progression and NF-KB activation. In this study, we show that the potent antitumor natural product epoxomicin specifically targets the proteasome. Utilizing biotinylated-epoxomicin as a molecular probe, we demonstrate that epoxomicin covalently binds to the LMP7, X, MECL1, and Z ca ... [Show more](#)

**3** Potent active against pre  
Kuhn, DJ; Chen, Nov 1 2007 | [Blood](#)  
The proteasome reversible prote  
not respond to i

**Author Information**  
Corresponding Address: Crews, CM (corresponding author)  
▼ Yale Univ, Dept Mol Cellular & Dev Biol, 219 Prospect St, New Haven, CT 06520 USA  
E-mail Addresses: craig.crews@yale.edu

Categories/Classification  
Research Areas: Science & Technology - Other Topics

**Funding**

**Funding agency**  
United States Department of Health & Human Services  
National Institutes of Health  
NIH National Cancer Institute  
United States National Institutes of Health  
National Institute of General Medical Sciences  
NIH National Cancer Institute

Show details Grant number

R01CA074967

R01CA074967-03  
CA74967

**RESEARCH & DISCOVERY**

**COMMERCIALIZATION**

**PRECLINICAL**

**APPROVAL & LAUNCH**

**CLINICAL**



© 2021 Clarivate 15

# InCites

A customized, citation-based research analytics tool

- Visualize the most impactful researchers & organizations
- Analyze institutional or competitor productivity
- Monitor collaborations
- Investigate competitors' research funding

Fast-track and fund your most promising researchers and the breakthrough science in your area.



# Derwent Innovation

The world's leading patent research & analytics platform

- Assess patentability and freedom-to-operate
- Validate invention novelty
- Monitor new entrants or threats
- Analyze competitors' patent portfolios
- Investigate any litigation on an in-licensing candidate

Scan the innovation landscape with speed and confidence.

WO2005105827A2

Add to Work file ▾ Mark record Watch record Download ▾ Translate ▾ Highlight Print

Key summary data

Patent	Dead	Publication date	2005-11-10
DWPI family	Alive View details	Expiration date	- <a href="#">View factors</a>
INPADOC family	Alive View details	Remaining life	-
Original assignee	PROTEOLIX INC, US	Domain Influence	38.29
Optimized assignee	AMGEN INC	Strategic Importance	7.49

Bibliography Abstract Classes/Indexing Legal status Family Claims Description

**Abstract**

DWPI abstract (US20050245435A1)

**Novelty**  
A compound for enzyme inhibition is new.

**Detailed description**  
A compound having a structure of formula (I), (II), (III), or its salt, Formula (I), or Formula (II), where A=C=O, C=S, or SO<sub>2</sub>, or optionally a covalent bond when adjacent to an occurrence of Z; L=absent or is C=O, C=S, or SO<sub>2</sub>, preferably L is absent or C=O; M=absent or is C<sub>1-12</sub> alkyl; Q=absent or is O, NH, or N-C<sub>1-6</sub> alkyl; Y=absent or is O, NH, N-C<sub>1-6</sub> alkyl, S, SO, SO<sub>2</sub>, CHOR<sup>10</sup>, or CHCO<sub>2</sub>R<sup>10</sup>; Z=O, S, NH, and N-C<sub>1-6</sub> alkyl, or optionally a covalent bond when adjacent to an occurrence of A; R<sup>1</sup>-R<sup>4</sup>-C<sub>1-6</sub> alkyl, C<sub>1-6</sub> hydroxalkyl, C<sub>1-6</sub> alkoxyalkyl, aryl, or C<sub>1-6</sub> aralkyl, any of which is optionally substituted with one or more of amide, amine, carboxylic acid (or its salt),

Original Title COMPOUNDS FOR ENZYME INHIBITION COMPOSES POUR L'INHIBITION ENZYMATIQUE

English Title COMPOUNDS FOR ENZYME INHIBITION

Assignee/Applicant Standardized: PROTEOLIX INC, SMYTH MARK S, LAIDIG GUY J, BORCHARDT RONALD T, BUNIN BARRY A, CREWS CRAIG M, MUSSER JOHN H, SCHNEEKLOTH JOHN S JR, CHABALA JOHN CLIFFORD

Original: PROTEOLIX INC., 225 Gateway Boulevard, South San Francisco, CA 94080, US

Case Activity

Powered by Darts-ip Part of Clarivate

WO2005105827A2 in case history  
20 The patent WO2005105827A2 appears in 20 cases.

PLAINTIFF	DEFENDANT	JURISDICTION
-	PROTEOLIX	Brazil
Onyx Therapeutics	Breckenridge Pharmaceutical	United States
Onyx Therapeutics	Cipla (+1 more party)	United States
-	Onyx Therapeutics	India
Onyx Therapeutics	Breckenridge Pharmaceutical	United States

15 more cases on Darts-ip

PROTEOLIX as plaintiff  
0 No cases found

Top inventors

Created 2020-09-10

Inventor	Record count
1. Other(1349)	1349
2. Buggy, Joseph J.(56)	56
3. GALMARINI, Carlos María(50)	50
4. Loury, David J.(48)	48
5. AVILÉS MARÍN, Pablo Manuel(47)	47
6. GARCÍA FERNÁNDEZ, Luis Francisco(46)	46
7. GUILLÉN NAVARRO, María José(46)	46
8. MONEO OCANA, Victoria(46)	46
9. Fyfe, Gwen(46)	46
10. Elias, Laurence(44)	44

PRECLINICAL

CLINICAL


© 2021 Clarivate

# Cortellis Drug Research Advisor – Target Druggability

*Game-changing interactive target ID & validation tool*

- **Quickly conduct target due diligence**
- **Verify if you have the best target**
- **Run a preliminary patent novelty check**
- **Investigate competition**
- **Prioritize your target**

Increase the likelihood of selecting the best-in-class or first-in-class asset.



Rank	Target main name	Gene symbol	Number of related records				
			Drugs	Experimental pharmacology	Animal models	Biomarker uses	Genetic evidence
1	Ubiquitin carboxyl-terminal hydrolase BAP1	[SYN] BAP1			0 (10)	1 (336)	1 (276)
2	Ubiquitin carboxyl-terminal hydrolase CYLD	[SYN] CYLD		2	0 (8)	12 (163)	9 (121)
3	Hyaluronan-binding protein 2	[SYN] HABP2		37	0 (2)	0 (144)	1 (26)
4	Integrin and metalloproteinase domain-containing protein 23	[SYN] ADAM23				0 (81)	1 (26)
5	A disintegrin and metalloproteinase with thrombospondin motifs 18	[SYN] ADAMTS18				1 (72)	1 (30)
6	A disintegrin and metalloproteinase with thrombospondin motifs 14	[SYN] ADAMTS14				0 (57)	1 (18)
7	Calpain-5	[SYN] CAPN5	0 (1)		0 (3)	0 (62)	1 (21)
8	A disintegrin and metalloproteinase with thrombospondin motifs 19	[SYN] ADAMTS19				0 (36)	1 (12)
9	Ubiquitin carboxyl-terminal hydrolase 49	[SYN] USP49				0 (17)	1 (12)
10	Ubiquitin carboxyl-terminal hydrolase 17-like protein 11	[SYN] USP17L11				0 (2)	1 (1)




# MetaCore

Bioinformatics suite for functional analysis of OMICs data

- Visualize how your target works
- Examine genetic evidence
- Gain a molecular understanding of the disease
- Identify novel biomarkers



Accelerate biomarker discovery and make better initial go/no-go decisions on your target.



**Multiple Myeloma**

Disease | Export | Build Network | Include Subfolders | Show low trust content

Causal Associations (by Gene)									
#	Gene	Alteration Level	Alteration Type	Alteration Subtype	Details	Abundance	Activity/Gain/Loss of Function	Normal/Pathology Concentration	Subcellular Localization Change
1	TGFBR2	DNA level	Epigenetics	Methylation	TGFBR2_HUMAN Methylation	up			Bone Marrow
2	CODIZC	DNA level	Gene rearrangements	Large Deletion	CODIZC_HUMAN Deletion				Plasma Cells
3	C4D	DNA level	Haplotypes/SNP		C4D_HUMAN rs2207212(I) / C4D_HUMAN rs2207212(C)				Blood
4	CODIZA	DNA level	Epigenetics	Methylation	CODIZA_HUMAN Methylation	up, Indifferent, down			Bone Marrow Cells, Bone Marrow, Leukocytes, Mononuclear, Plasma Cells, Blood
5	IILB	DNA level	Haplotypes/SNP		IILB_HUMAN rs11363627(C) / IILB_HUMAN rs11363627(C)				Leukocytes, Mononuclear
6	LAG3	DNA level	Haplotypes/SNP		LAG3_HUMAN rs3782735(A) / LAG3_HUMAN rs3782735(A)				Blood
7	IILB	DNA level	Haplotypes/SNP		IILB_HUMAN rs11363627(C)				Leukocytes, Mononuclear
8	LAG3	DNA level	Haplotypes/SNP		LAG3_HUMAN rs2363094(C) / LAG3_HUMAN rs2363094(C)				Blood
9	CYP2C9	DNA level	Haplotypes/SNP		CYP2C9_HUMAN rs1134980(C)				Blood
10	IIL6-AS1	DNA level	Haplotypes/SNP		IIL6_HUMAN rs1801079(A)				Blood




# Cortellis Drug Discovery Intelligence

Comprehensive biology, chemistry & pharmacology data in one place

- Identify, prioritize and select drug candidates
- Monitor the target landscape
- Inspect competitor's activities
- Benchmark experimental performance
- Examine drug-drug interactions

Make better informed go/no-go pipeline and competitor-based decisions.



Entry Number	Highest Phase	Code Name	Generic Name	Brand Name	Product Category	Therapeutic Group	Mechanism of Action	Organization
91537	Withdrawn - 2007	Bay-s-128 RP-9921	Aprotinin	Trasylol		Breast Cancer Therapy	Serine Protease Inhibitors	Bayer (Originator) National Cancer Institute (NCI)
211732	Launched - 1997	AG-1343 AG-1346 ARV-SR0121 LY-312857	Nelfinavir mesilate	Viracept	Radiosensitizers	Anti-Coronavirus (CoV) Drugs	HIV-1 Protease Inhibitors	Agouron (Originator) Japan Tobacco (JT)
199183	Launched - 1996	L-735524 MK-639	Indinavir sulfate	Crixivan		Anti-HIV Agents	Viral Fusion Inhibitors	Maastricht Radiation Oncology (MAASTRO)
						Kaposi's Sarcoma Therapy	HIV Protease Inhibitors	Istituto Superiore di Sanita MSD KK (Originator) Merck & Co. (Originator)




**Drug-Drug Interactions**

Prescription	0	0	0	8	14	0
	● Contraindicated	● Not Recommended	● Warning/Precaution	● No Interaction	● Beneficial	● Undisclosed

Showing 1-20 of 22 Drug-Drug Interactions records for "Carfilzomib"

Evaluated Entity	Interacting Entity	Interaction Type	Outcome	Prescription	Population / Study Model
Dexamethasone	Carfilzomib	Pharmacokinetics (ADME)	No Interaction	No Interaction	Humans
Carfilzomib	Dexamethasone	Pharmacokinetics (ADME)	No Interaction	No Interaction	Humans
Lenalidomide	Carfilzomib	Pharmacodynamics	Pharmacodynamics	Beneficial	Humans/Adult/Multiple myeloma
Lenalidomide	Carfilzomib	Pharmacodynamics	Pharmacodynamics	Beneficial	Humans/Asian/Adult/Multiple myeloma
Selinexor	Carfilzomib	Pharmacodynamics	Pharmacodynamics	Beneficial	Mice/Multiple myeloma;Severe combined immunodeficiency disease (SCID)





© 2021 Clarivate

20

# Cortellis CDDI – Biomarkers

Broadest coverage of biomarker uses at every stage of Drug R&D

- Identify biomarkers to stratify your patients
- Better understand disease pathology
- Examine a biomarker's uses and level of validity
- Classify biomarkers into lifecycle phases

Increase your probability of success in clinical trials, and accelerate drug development.

Biomarkers Biomarker Uses Biomarker Kits

Apply Filters Sorted by relevance

Biomarker Uses - C... (620) x

Showing 1-20 of 8544 Biomarker Uses records for "Protease Inhibitors"

Biomarker Name	Indication	Population	Role	Highest Validity	Drugs	Supporting	Supporting / Conflicting	Conflicting	
Alanine transaminase	Sepsis, severe	Adult	Monitoring Treatment Efficacy	Late Studies in Humans	1	1	0	0	<a href="#">View Use</a>
Creatine Kinase, MB Form	Systemic inflammatory response syndrome	Cardiovascular Disorders	Monitoring Treatment Efficacy	Late Studies in Humans	1	1	0	0	<a href="#">View Use</a>
Antithrombin III-protease complex	Occlusion, arterial coronary	High Risk	Monitoring Treatment Efficacy	Late Studies in Humans	1	1	0	0	<a href="#">View Use</a>
Hemoglobin	Occlusion, arterial coronary	High Risk	Monitoring Treatment Efficacy	Late Studies in Humans	1	1	0	0	<a href="#">View Use</a>
Lactic Acid	Sepsis, severe	Adult	Monitoring Treatment Efficacy	Late Studies in Humans	1	1	0	0	<a href="#">View Use</a>


Biomarker Use Record Biomarker Kits

General Information

Biomarker Name	Caspase-3	Role	Monitoring Treatment Efficacy
Indication Type	Condition	Highest Validity	Early Studies in Humans
Indication	Multiple myeloma	Population	All

Techniques & Substrates

Technique	Substrate	Validity	Drugs	Genetic Variants	Supporting	Supporting/Conflicting	Conflicting
Not specified	Not specified	Experimental	4	0	3	0	0
Spectrophotometry	Cell lysates	Experimental	2	0	1	1	0
High Throughput Nucleotide Sequencing	DNA	Early Studies in Humans	0	0	0	0	1
Real Time PCR	mRNA	Experimental	1	0	1	0	0
Immunofluorescence	Cell lysates	Experimental	1	0	1	0	0




# OFF-X

The largest translational safety & toxicity intelligence portal

- Anticipate toxicity & safety events
- Examine the safety profile of in-licensing candidates
- Investigate the toxicity of competing treatments
- Differentiate your asset
- Monitor regulatory concerns and liabilities

Design better and safer protocols which mitigate unintended risks to patients.




# PHASE 2 MARKET ASSESSMENT

# Competitive Intelligence

The trusted and industry-leading drug pipeline database

- Efficiently track the competitive landscape
- Understand competitors' product positioning
- Differentiate your asset
- Assess expected product performance
- Determine potential market share
- Examine safety findings

Confidently make critical product, portfolio and competitor-based decisions.



# Deals Intelligence

The gold standard biopharma deals database

- Quickly examine deal valuations & financial terms
- Easily benchmark funding, licensing, and M&A deals
- Analyze potential partners' deal history
- Inform deal negotiations
- Easily visualize deal trends & deal predictions (Q2 2021)

Make confident buy or build decisions and strike your best possible deal.


**Onyx acquires Proteolix**

Snapshot	Highlight	Search Terms & Synonyms	< Previous	Next >												
Drugs	EVENTS															
Patents	SUMMARY															
Contract	In October 2009, Onyx Pharmaceuticals announced that it is acquiring the company. The acquisition completed [1057285]. In January 2011, the parties entered into a definitive agreement to amend the terms of the acquisition. The parties entered into a definitive agreement to amend the terms of the acquisition completed [1057285]. In January 2011, the parties entered into a definitive agreement to amend the terms of the acquisition completed [1057285]. In January 2011, the parties entered into a definitive agreement to amend the terms of the acquisition completed [1057285]. In January 2011, the parties entered into a definitive agreement to amend the terms of the acquisition completed [1057285].															
Events	<b>TIMELINE</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>Date</th> <th>Event Type</th> <th>Description</th> </tr> </thead> <tbody> <tr> <td>20-Jul-2012</td> <td>Other Deal Update</td> <td>- In July 2012, Kyprolis (carfilzomib) was approved by the FDA. \$170M of the total contingent consideration for the acquisition was attributable to this event.</td> </tr> <tr> <td>27-Jan-2011</td> <td>Deal Amendment</td> <td>- In January 2011, the parties entered into a definitive agreement to amend the terms of the acquisition completed [1057285]. - The parties also amended milestone payment terms. The parties amended the milestones to \$130 million if the event occurs on or before November 16, 2011, and \$100 million if the event occurs on or before November 16, 2012.</td> </tr> <tr> <td>16-Nov-2009</td> <td>Deal Completed</td> <td>- On November 16, 2009, the acquisition completed [1057285].</td> </tr> </tbody> </table>				Date	Event Type	Description	20-Jul-2012	Other Deal Update	- In July 2012, Kyprolis (carfilzomib) was approved by the FDA. \$170M of the total contingent consideration for the acquisition was attributable to this event.	27-Jan-2011	Deal Amendment	- In January 2011, the parties entered into a definitive agreement to amend the terms of the acquisition completed [1057285]. - The parties also amended milestone payment terms. The parties amended the milestones to \$130 million if the event occurs on or before November 16, 2011, and \$100 million if the event occurs on or before November 16, 2012.	16-Nov-2009	Deal Completed	- On November 16, 2009, the acquisition completed [1057285].
Date	Event Type	Description														
20-Jul-2012	Other Deal Update	- In July 2012, Kyprolis (carfilzomib) was approved by the FDA. \$170M of the total contingent consideration for the acquisition was attributable to this event.														
27-Jan-2011	Deal Amendment	- In January 2011, the parties entered into a definitive agreement to amend the terms of the acquisition completed [1057285]. - The parties also amended milestone payment terms. The parties amended the milestones to \$130 million if the event occurs on or before November 16, 2011, and \$100 million if the event occurs on or before November 16, 2012.														
16-Nov-2009	Deal Completed	- On November 16, 2009, the acquisition completed [1057285].														
Financial																
Venture Funding																
Mergers & Acquisition																
Sources																
Similar Deals	<a href="#">New</a>															

**Amgen acquires Onyx Pharmaceuticals**

Snapshot	Highlight	Search Terms & Synonyms	< Previous	Next >																																			
Drugs	EVENTS																																						
Patents	SUMMARY																																						
Contract	In June 2013, Amgen made an unsolicited offer to acquire Onyx Pharmaceuticals [1446196]. In August 2013, Amgen would acquire all of the outstanding shares of Onyx for net of estimated Onyx cash [1469238]. In September 2013, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, was terminated early on September 18, 2013 which was scheduled to expire on September 23, 2013 [1478623]. On October 1, 2013 Amgen completed the acquisition of Onyx Pharmaceuticals [1483015].																																						
Events	<b>TIMELINE</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>Date</th> <th>Event Type</th> <th>Description</th> <th>Drug(s)</th> <th>Stage</th> <th>Payment Type</th> <th>Value (USD m)</th> </tr> </thead> <tbody> <tr> <td>01-Oct-2013</td> <td>Deal Completed</td> <td>- On October 1, 2013 Amgen completed the acquisition of Onyx Pharmaceuticals for \$125/share in cash, valued at \$9.7 billion net of estimated Onyx cash [1483015].</td> <td></td> <td></td> <td>Upfront Payment to Principal Company;</td> <td>=9,700.00</td> </tr> <tr> <td>18-Sep-2013</td> <td>Other Deal Update</td> <td>- In September 2013, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, was terminated early on September 18, 2013 which was scheduled to expire on September 23, 2013 [1478623].</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td></td> <td>Other Deal Update</td> <td>- In August 2013, Amgen would acquire all of the outstanding shares of Onyx for \$125/share in cash, valued at \$10.4 billion, or \$9.7 billion net of estimated Onyx cash [1469238].</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td></td> <td>Original Deal</td> <td>- In June 2013, Amgen made an unsolicited offer to acquire Onyx Pharmaceuticals for \$120/share in cash, a 38% premium to Onyx' closing price on June 28, 2013 valued at approximately \$8.76 billion.  - Onyx Pharmaceuticals develops and commercializes therapies for cancer and the main products would include:  - Nexavar (sorafenib tosylate) co-developed and co-marketed with Bayer for kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer (hepatocellular carcinoma). (See 4/1994 transaction).  - Kyprolis (carfilzomib) approved for multiple myeloma and solid tumors.</td> <td></td> <td></td> <td>Registered</td> <td></td> </tr> </tbody> </table>				Date	Event Type	Description	Drug(s)	Stage	Payment Type	Value (USD m)	01-Oct-2013	Deal Completed	- On October 1, 2013 Amgen completed the acquisition of Onyx Pharmaceuticals for \$125/share in cash, valued at \$9.7 billion net of estimated Onyx cash [1483015].			Upfront Payment to Principal Company;	=9,700.00	18-Sep-2013	Other Deal Update	- In September 2013, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, was terminated early on September 18, 2013 which was scheduled to expire on September 23, 2013 [1478623].						Other Deal Update	- In August 2013, Amgen would acquire all of the outstanding shares of Onyx for \$125/share in cash, valued at \$10.4 billion, or \$9.7 billion net of estimated Onyx cash [1469238].						Original Deal	- In June 2013, Amgen made an unsolicited offer to acquire Onyx Pharmaceuticals for \$120/share in cash, a 38% premium to Onyx' closing price on June 28, 2013 valued at approximately \$8.76 billion.  - Onyx Pharmaceuticals develops and commercializes therapies for cancer and the main products would include:  - Nexavar (sorafenib tosylate) co-developed and co-marketed with Bayer for kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer (hepatocellular carcinoma). (See 4/1994 transaction).  - Kyprolis (carfilzomib) approved for multiple myeloma and solid tumors.			Registered	
Date	Event Type	Description	Drug(s)	Stage	Payment Type	Value (USD m)																																	
01-Oct-2013	Deal Completed	- On October 1, 2013 Amgen completed the acquisition of Onyx Pharmaceuticals for \$125/share in cash, valued at \$9.7 billion net of estimated Onyx cash [1483015].			Upfront Payment to Principal Company;	=9,700.00																																	
18-Sep-2013	Other Deal Update	- In September 2013, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, was terminated early on September 18, 2013 which was scheduled to expire on September 23, 2013 [1478623].																																					
	Other Deal Update	- In August 2013, Amgen would acquire all of the outstanding shares of Onyx for \$125/share in cash, valued at \$10.4 billion, or \$9.7 billion net of estimated Onyx cash [1469238].																																					
	Original Deal	- In June 2013, Amgen made an unsolicited offer to acquire Onyx Pharmaceuticals for \$120/share in cash, a 38% premium to Onyx' closing price on June 28, 2013 valued at approximately \$8.76 billion.  - Onyx Pharmaceuticals develops and commercializes therapies for cancer and the main products would include:  - Nexavar (sorafenib tosylate) co-developed and co-marketed with Bayer for kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer (hepatocellular carcinoma). (See 4/1994 transaction).  - Kyprolis (carfilzomib) approved for multiple myeloma and solid tumors.			Registered																																		
Financial																																							
Venture Funding																																							
Mergers & Acquisition																																							

**Deal Size by Phase**



Legend: Average Deal Size (Dark Green), Median Deal Size (Light Green)

Status	Average Deal Size	Median Deal Size
Launched	2835	~100
Registered	2868	~200
Pre-registration	383	~100
Phase 3 Clinical	788	~100
Phase 2 Clinical	510	~100
Phase 1 Clinical	756	~100
Clinical	590	~100
Preliminary	~100	~100
Discovery	~100	~100
Status	~100	~100

**Data**

Drugs Highest Status (Deal Start)	Deal Counts	Deal Size Counts (Total Projected Current)	Deal Size Sum (Total Projected Current)	Deal Size Average	Deal Size Max	Deal Size Min	Upfront Payment Count	Upfront Sum (USD M)	Upfront Average
Launched	12	12	34024.65	2835.39	11400	4.25	8	23727.08	2965.89
Registered	6	6	17210.5	2868.42	8800	35.5	6	16759.7	2793.28
Pre-registration	1	1	0.56	0.56	0.56	0.56	1	0.56	0.56
Phase 3 Clinical	18	18	6887.3	382.63	1275	0.47	13	1617.87	124.45
Phase 2 Clinical	27	27	21275.63	787.99	10434	0.69	20	3730.9	186.55
Phase 1 Clinical	8	8	4078.46	509.81	1878	0.65	7	144.1	20.59
Preliminary	20	20	15126.27	756.31	5046	0.7	13	339.55	26.12
Discovery	17	17	10022.36	589.55	3665.5	4.87	13	867.83	66.76
Grand Total	112	112	110161.23	983.58	11400	0.47	82	47188.09	575.46



# PHASE 3 CLINICAL TESTING

# Cortellis Clinical Trials Intelligence

*Insights into the landscape of ongoing clinical trials*

- Evaluate the design of precedent studies
- Benchmark patient enrollment and timelines
- Define the right endpoints and select biomarkers
- Pinpoint adverse events
- Monitor competing trials
- Search for experienced sites
- Prioritize sites by performance, availability and competition

13733 Clinical Trial results with filter(s) applied: Coronavirus disease 19 infection																																																																																													
Report Type		Results	Per page :	10	Sort by:																																																																																								
Show selected only																																																																																													
<b>Clinical Trials (483380)</b>																																																																																													
Refine Search																																																																																													
Search within Results																																																																																													
Search																																																																																													
Condition																																																																																													
Filters [1] <span style="float: right;">Clear</span>																																																																																													
<input checked="" type="checkbox"/> <a href="#">Coronavirus disease 19 infection on (13733)</a> <a href="#">Show all filters</a>																																																																																													
Patient Segment																																																																																													
Filters [1] <span style="float: right;">Clear</span>																																																																																													
<input checked="" type="checkbox"/> <a href="#">A Clinical Study of Nasya and Rasayan in Post COVID-19 Syndrome</a> <a href="#">... ...</a>																																																																																													
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>Site Name</th> <th>City</th> <th>State / Province / County</th> <th>Postal Code</th> <th>Country / Territory</th> <th>Total Trial Count</th> <th>Matched Trial Count</th> <th>Top Therapy Areas</th> </tr> </thead> <tbody> <tr> <td><a href="#">University Hospital for Tumors Ambulance</a></td> <td>Zagreb</td> <td>Grad Zagreb</td> <td>10000</td> <td>Croatia</td> <td>276</td> <td>33</td> <td>Cancer; Gastrointestinal; Neurology/Psychiatric;</td> </tr> <tr> <td><a href="#">Sisters of Charity Hospital</a></td> <td>Zagreb</td> <td>Grad Zagreb</td> <td>10000</td> <td>Croatia</td> <td>80</td> <td>13</td> <td>Cancer; Neurology/Psychiatry</td> </tr> <tr> <td><a href="#">Clinical Hospital Dubrava</a></td> <td>Dubrava</td> <td>Zagrebacka</td> <td>10000</td> <td>Croatia</td> <td></td> <td></td> <td></td> </tr> <tr> <td><a href="#">Clinical Hospital Center Rijeka</a></td> <td>Rijeka</td> <td>Primorsko-Goranska</td> <td>51000</td> <td>Croatia</td> <td></td> <td></td> <td></td> </tr> <tr> <td><a href="#">KBC Split</a></td> <td>Split</td> <td>Splitsko-Dalmatinska</td> <td>21000</td> <td>Croatia</td> <td></td> <td></td> <td></td> </tr> <tr> <td><a href="#">Zadar General Hospital</a></td> <td>Zadar</td> <td>Zadarska</td> <td>23000</td> <td>Croatia</td> <td></td> <td></td> <td></td> </tr> <tr> <td><a href="#">Special Hospital for Medical Rehabilitation</a></td> <td>Krapinske Toplice</td> <td>Krapinsko-Zagorska</td> <td>49217</td> <td>Croatia</td> <td></td> <td></td> <td></td> </tr> <tr> <td><a href="#">Merkur Clinical Hospital</a></td> <td>Zagreb</td> <td>Grad Zagreb</td> <td>10000</td> <td>Croatia</td> <td></td> <td></td> <td></td> </tr> <tr> <td><a href="#">Sveti Duh</a></td> <td>Zagreb</td> <td>Grad Zagreb</td> <td>10000</td> <td>Croatia</td> <td></td> <td></td> <td></td> </tr> <tr> <td><a href="#">General Hospital Karlovac</a></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>						Site Name	City	State / Province / County	Postal Code	Country / Territory	Total Trial Count	Matched Trial Count	Top Therapy Areas	<a href="#">University Hospital for Tumors Ambulance</a>	Zagreb	Grad Zagreb	10000	Croatia	276	33	Cancer; Gastrointestinal; Neurology/Psychiatric;	<a href="#">Sisters of Charity Hospital</a>	Zagreb	Grad Zagreb	10000	Croatia	80	13	Cancer; Neurology/Psychiatry	<a href="#">Clinical Hospital Dubrava</a>	Dubrava	Zagrebacka	10000	Croatia				<a href="#">Clinical Hospital Center Rijeka</a>	Rijeka	Primorsko-Goranska	51000	Croatia				<a href="#">KBC Split</a>	Split	Splitsko-Dalmatinska	21000	Croatia				<a href="#">Zadar General Hospital</a>	Zadar	Zadarska	23000	Croatia				<a href="#">Special Hospital for Medical Rehabilitation</a>	Krapinske Toplice	Krapinsko-Zagorska	49217	Croatia				<a href="#">Merkur Clinical Hospital</a>	Zagreb	Grad Zagreb	10000	Croatia				<a href="#">Sveti Duh</a>	Zagreb	Grad Zagreb	10000	Croatia				<a href="#">General Hospital Karlovac</a>							
Site Name	City	State / Province / County	Postal Code	Country / Territory	Total Trial Count	Matched Trial Count	Top Therapy Areas																																																																																						
<a href="#">University Hospital for Tumors Ambulance</a>	Zagreb	Grad Zagreb	10000	Croatia	276	33	Cancer; Gastrointestinal; Neurology/Psychiatric;																																																																																						
<a href="#">Sisters of Charity Hospital</a>	Zagreb	Grad Zagreb	10000	Croatia	80	13	Cancer; Neurology/Psychiatry																																																																																						
<a href="#">Clinical Hospital Dubrava</a>	Dubrava	Zagrebacka	10000	Croatia																																																																																									
<a href="#">Clinical Hospital Center Rijeka</a>	Rijeka	Primorsko-Goranska	51000	Croatia																																																																																									
<a href="#">KBC Split</a>	Split	Splitsko-Dalmatinska	21000	Croatia																																																																																									
<a href="#">Zadar General Hospital</a>	Zadar	Zadarska	23000	Croatia																																																																																									
<a href="#">Special Hospital for Medical Rehabilitation</a>	Krapinske Toplice	Krapinsko-Zagorska	49217	Croatia																																																																																									
<a href="#">Merkur Clinical Hospital</a>	Zagreb	Grad Zagreb	10000	Croatia																																																																																									
<a href="#">Sveti Duh</a>	Zagreb	Grad Zagreb	10000	Croatia																																																																																									
<a href="#">General Hospital Karlovac</a>																																																																																													

**University Hospital for Tumors Ambulance**

Zagreb Grad Zagreb Croatia 10000

Matched Condition: [Cardiovascular disease](#)

Top Therapy Areas: [Cancer](#) [Gastrointestinal](#) [Neurology/Psychiatric](#)

Top Sponsors: [Roche Holding AG](#) [F Hoffmann-La Roche AG](#) [AbbVie Inc](#)

Total Trials: **276** Matched Trials: **33** Ongoing Trials: **74**

**Site Statistics**

<b>10</b> Ongoing Matched Trials	<b>0</b> Completed Total Trials in past 12 months	<b>0</b> Completed Matched Trials in past 12 months
-------------------------------------	------------------------------------------------------	--------------------------------------------------------

22 Feb 2021

**400K+**  
Global clinical trials

**2900+**  
Diseases and therapeutic areas

**200K+**  
Clinical sites across 200+ countries

**39**  
Trial registries

[Download the factsheet →](#)
© 2021 Clarivate
27

Cortellis™



Clarivate  
Cortellis™

# Cortellis Clinical Trials Inntelligence

Insight on global trial sites


- Search for experienced sites
- Prioritize sites by performance, availability and competition
- Validate CRO input
- Uncover high level incidence and prevalence
- Identify experienced investigators (2022)

Position your clinical trials for greater success by selecting the best sites.



# Summary

Unprecedented value from an end-to-end lifecycle perspective that empowers more proactive and better-informed decisions with speed and confidence.



Every product we use, medical treatment we receive and service we consume has been imagined, created and improved in a continuous, connected cycle of innovation.

**Clarivate** operates at the heart of that lifecycle. We give our customers the lens of clarity—the insights they need to turn bold ideas into life-changing innovations

# Appendices

# Data Citation Index

The Data Citation Index makes it easy to bring research data into your workflow.



Researchers

- **Save time** spent looking for data by searching across content from **over 430** repositories in one place.
- **Track citations to the data and software you have deposited.**
- **10.4 million total items indexed**
- Provides data studies from **1900-present**



Librarians

- **Promote the value and importance of sharing data** & following the best data management practices.
- **Provide a trusted reference** for faculty unsure of where to deposit data.

## Master Repository List



Your key to European statistics



Genome Portal




# Drug Timeline & Success Rates

First-to-market machine learning-based predictive analytics tool

- Confidently make critical portfolio decisions
- Monitor competitors' success rates & timelines
- Gain a reliable 3rd party validation
- Inform portfolio planning & prioritization.

Yield smarter portfolio planning and R&D investment decisions for long term success.



# Decision Resource Group (DRG)

Find out what impact Covid-19 is having on the medtech/pharma markets.

## COVID-19

Notifications Off

At a Glance

COVID-19 ▾

Meet The Team

### Table of contents

Expand all

Search within Content



#### GEOGRAPHIES

✓ US Trend Tracking

✓ Healthcare Facility Targeting

✓ US Market Forecast

Updates

✓ Canada Market Forecast

Updates

✓ Europe Market Forecast

Updates

+ Europe Impact Assessment

Summary

+ Aesthetics

### COVID-19 Impact Assessment Summary, by Therapy Area, Europe

Factor	Aesthetics	Cardiovascular	Dental	Endoscopy and Open Surgery	Gynecology	Imaging	Orthopedics
Procedure Volumes	Strong	Moderate	Strong	Strong	Moderate	Moderate	Moderate
ASPs	Strong	Weak	Moderate	Weak	Weak	Moderate	Weak
New Product Launches	Moderate	Moderate	Moderate	Moderate	Weak	Weak	Strong
Clinical Trials	Moderate	Strong	Moderate	Moderate	Moderate	—	Moderate
Supply Chain	Weak	Moderate	Weak	Moderate	Moderate	Moderate	Moderate

## COVID-19 Market Impact Forecast Methodology

DISPLAY



3

0

0

Last updated 29 January 2021

### Determining and forecasting the impact on medtech markets

#### COVID-19: Determining and forecasting the impact on medtech markets

The forecast within each Medtech 360 market analysis was created using these primary modeling components:


##### COVID-19 Impact Forecast: Primary Modeling Components



Determining initial procedure deferral during the time of peak pandemic impact



Estimating the proportion of deferred procedures that will be recovered after the impact peak



© 2020 DR/Decision Resources, LLC. All rights reserved.

1

[See today's BioWorld](#)

## Novavax's COVID-19 vaccine shows 100% protection against severe disease



Credit: Novavax Inc.

By Lee Landenberger March 12, 2021



Data from two [Novavax Inc.](#) clinical trials show its COVID-19 vaccine had 100% protection against severe disease, including hospitalization and death, paving the way for an emergency use authorization submission in the U.S.

Mild and moderate COVID-19 was dramatically reduced in both studies, according to the data, and some efficacy was confirmed in variant strains.

Final efficacy numbers from Novavax's phase III study of [NVX-CoV2373](#) revealed the vaccine was 96.4% effective against mild, moderate and severe disease caused by the original COVID-19 strain. The efficacy numbers are very close to those

# **Discovery & Translational Science (DTS) Consulting, Data & Insights**

Accelerate your research with advanced analytics and actionable insights

*Deep domain knowledge and advanced data science capabilities*

## **Innovation Monitoring**

- Predict an emerging technology that has the potential to be the next blockbuster

### **RWD-based KOL Identification**

- Find the top thought leaders to uncover unmet medical needs and emerging research areas

## **Target Identification / Biomarker Discovery**

- Identify and systematically prioritize targets and biomarkers for higher chances of drug development success.

### **Patient Stratification**

- Classify patient subgroups by drug response & resistance

## **Computational Biology Methods for Drug Discovery (CBDD)**

- Discover novel approaches to network and pathway analysis through collaboration with industry leaders & Innovators

## **Indication Prioritization**

- Systematically find the most meaningful indications for a given target of interest

## **Mechanism Reconstruction**


- Reconstruct biological mechanisms from OMICs data

## **Toxicity Prediction**

- Understand the potential safety risk and rank-order your lead compounds relative to potential toxicity

## **Drug Repurposing**

- Find other disease areas for your existing product to extend revenues and patent life



# Consulting Services for Clinical Development

Transform and accelerate your clinical trials

*Deep domain knowledge and hands-on industry expertise*

## RWD-based Integrated Patient Journey

- Understand drug performance in the real world in contrast to clinical setting through real world data
- Uncover where in the patient journey the therapy can be introduced to address the unmet medical need or patient pain points
- Identify adverse events experienced by the patients and what the clinical and economic impacts are from those
- Pinpoint influence levers to inform commercial and patient engagement strategies

## Pricing & Reimbursement

- Inform clinical development strategy and avoid costly amendments by understanding the current value-based pricing and contracting strategies and activities

## Health Economics Outcomes Research (HEOR)

- Avoid costly protocol amendments by incorporating economic endpoints into the trial design for evidence of the product's economic value for reimbursement decisions
- Conduct an evidence gap analysis and develop patient outcomes assessments for successful market access

## Intelligent Trials: Study & Site Optimization

- Optimize your study design, pick the best performing sites, and accurately size and locate your target populations



# Consulting Services for Clinical Operations

Optimize your clinical performance

*Deep domain knowledge and hands-on industry expertise*

## RWD-based KOL Identification


- Discover and profile the best thought leaders in your disease area to consult with
- Segment physicians based on location, disease area, patients treated, procedures performed, hospital or care facility affiliations as well as their referrals

## Center for Medicines Research (CMR) International

- Benchmark clinical performance of peers to optimize operations and cycle times
- Inform feasibility analysis and clinical strategy by leveraging country, study, and site level performance data

## RWD-based Patient Finder

- Identify hospitals or practices that have the highest patient groups of interest, and physicians that manage patient groups within the trial inclusion criteria
- Influence physicians to enroll patients into your clinical study



# Additional Resources

# Web of Science Mobile App -My Research Assistant “MyRA” brings the Power of WoS to the Palm of your Hand

The diagram illustrates the features of the MyRA mobile app, which integrates various research and citation tools. It shows three main screens: a login screen, a news feed screen, and a detailed article view screen.

- Create an account and log in using Clarivate One Account.** (Top right)
- News feeds as your home screen, alerting you to the latest articles you are interested in.** (Bottom left)
- Save articles to your reading list for later viewing.** (Bottom center)
- Read the full text article on the publisher website within the app.** (Bottom right)
- Share articles via other apps on your device.** (Top right)
- Dive into the citation network with cited, citing, and related articles, and direct links to author, research area, journal, and funder searches.** (Top right)

[Apple download](#)

[Google Play download](#)

[Learn more](#)

# Additional resources

[Web of Science Learning](#) >

[Cortellis information](#)



[Web of Science Academy](#) >

[Events & Webinars](#) >


[LibGuides](#) >

[Videos](#) >

[Web of Science Blog](#) >

[Web of Science news hub](#) >

[Researcher Recognition](#) >



# Customer Service - Available 24x5

## [support.clarivate.com/ScientificandAcademicResearch](https://support.clarivate.com/ScientificandAcademicResearch)



LIVE CHAT

Click [here](#) to reach a WoS agent



PHONE

Dial +44 8003288044



EMAIL or WEBFORM

[WoSG.support@clarivate.com](mailto:WoSG.support@clarivate.com) or click [here](#) to send us a Webform



KNOWLEDGE BASE

Click [here](#) to visit our extensive Knowledge Base


Links to popular articles include: [Remote Access to WoS](#), [h-index Information](#)

# Resources for teaching and learning

Stay up to date on product developments, and provide on-demand support for students and faculty

## Web of Science Learning Page


Point students and faculty to “how to” content available 24/7.



[Learning Page](#)

## LibGuides

Save time updating your LibGuides by reusing pages from ours.



[clarivate.libguides.com/home](#)

## Librarian Toolkit


Quick links to individual databases, factsheets, and more.



[View Toolkit](#)

## Web of Science Academy

Online training supporting academics in conducting research with integrity



[Join our Web of Science Academy](#)



# Köszönöm!

